Nobelpharma

What Nobelpharma does

Nobelpharma America, LLC is the US operating subsidiary of Nobelpharma Co., Ltd. (founded 2003 in Tokyo, Japan), focused on developing and commercializing drugs and medical devices for rare and underserved diseases that larger pharmaceutical companies tend to overlook due to small patient populations. The company was established in Bethesda, Maryland in 2019 as Nobelpharma's first global subsidiary, intentionally located near US researchers, regulators, and patient advocacy organizations. Nobelpharma's stated corporate philosophy is to develop First-In-Class and Best-In-Class therapeutics, and the parent reports an R&D approval rate in Japan on par with large pharmaceutical companies over its first decade of operations.

The company's sole commercially available US product is HYFTOR (sirolimus topical gel) 0.2%, which received FDA approval in April 2022 as the first FDA-approved topical treatment for facial angiofibroma associated with Tuberous Sclerosis Complex (TSC), a rare genetic disease that is the leading genetic cause of epilepsy and affects multiple organ systems. HYFTOR is a topical mTOR inhibitor formulation that represented a novel route of administration (topical versus systemic) for an established compound. The product became commercially available in the United States in August 2022, and in January 2023 Nobelpharma America launched a dedicated disease education website focused on TSC-associated facial angiofibroma to drive patient and provider awareness. Nobelpharma maintains a broader pipeline of drug and medical device candidates targeting neglected rare diseases.

Nobelpharma America operates a specialty pharmaceutical commercial model. Products are distributed through specialty pharmacy channels supported by patient access programs, with marketing executed via enterprise field sales targeting dermatologists, neurologists, and other specialists treating TSC. Community-led engagement, including title sponsorship of the TSC Alliance's annual Step Forward to Cure TSC walk across 14 US locations, supplements traditional medical conference presence and PR/newswire distribution. The company employs 11–50 staff in the United States and serves patient populations while collaborating with healthcare providers in the rare-disease space across North America and Asia-Pacific (Japan, China).

Name

Nobelpharma

Legal name

Nobelpharma America, LLC

Website

https://nobelpharma-us.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Nobelpharma America, LLC is the US subsidiary of Japan's Nobelpharma Co., Ltd., developing and commercializing drugs for rare and underserved diseases. Its lead product is HYFTOR, the first FDA-approved topical treatment for facial angiofibroma associated with Tuberous Sclerosis Complex.

Ownership category

akta.pro rank

Product category

Rare Disease Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Rare Dermatology Disorder Therapies (HLAIAIAM)

Keywords

• Rare disease pharmaceuticals
• Orphan drug development
• Topical drug formulations
• Tuberous sclerosis treatment
• Specialty pharmaceutical products

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Nobelpharma generates revenue through the sale of FDA-approved pharmaceutical products, specifically drugs for rare genetic diseases that have limited or no other treatment options.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Nobelpharma develops, manufactures, and commercializes pharmaceutical products and medical devices targeting rare, neglected, and underserved diseases. Its commercially available product, HYFTOR (sirolimus topical gel) 0.2%, is the first FDA-approved topical treatment for facial angiofibroma associated with Tuberous Sclerosis Complex (TSC). The company pursues First-In-Class and Best-In-Class drug candidates through collaborations with worldwide experts and continues to expand its pipeline of treatments for conditions with limited therapeutic options.

Product overview

Nobelpharma is a purpose-driven pharmaceutical company focused on developing drugs and medical devices for rare and underserved conditions. The company operates a pipeline-based development model, with its primary commercial product being HYFTOR (sirolimus topical gel) 0.2%, the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC). Nobelpharma continues to develop additional drug and medical device candidates through its R&D pipeline for conditions with limited or no treatment options.

Differentiator

Problem solved

Functional benefit

Products and services

• HYFTOR (sirolimus topical gel) 0.2% FDA-approved topical mTOR inhibitor gel for the treatment of facial angiofibroma associated with Tuberous Sclerosis Complex (TSC). It is the first FDA-approved topical treatment for this indication and is prescribed by dermatologists and other specialists for TSC patients.

Quantifiable outcome

• First FDA-approved topical treatment for facial angiofibroma associated with TSC

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• TSC AlliancecoreGTM or Marketing Partner · 9 April 2026Nobelpharma America serves as title sponsor for the TSC Alliance's 25th Annual Step Forward to Cure TSC walk event (April 11 to June 6, 2026). The event takes place at 14 in-person locations across the U.S. with virtual participation globally. Proceeds fund research and support programs for TSC, a rare genetic disease affecting multiple organs and the leading genetic cause of epilepsy.
• TSC AlliancecoreStrategic or Co-development PartnerNobelpharma partnered with TSC Alliance for Rare Disease Day and has been recognized by the alliance for its commitment to the TSC community. The partnership focuses on supporting patients with Tuberous Sclerosis Complex through disease awareness and research funding.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ultragenyx Pharmaceutical: Commercial-stage rare genetic disease biotech with multiple approved therapies and an orphan-disease focus. Directly comparable to Nobelpharma on rare-disease specialization, small patient populations, and First/Best-in-class positioning strategy.
• BioMarin Pharmaceutical: Specialty rare-disease pharma with a portfolio of approved orphan drugs across multiple indications. Comparable business model to Nobelpharma: orphan exclusivity, small patient populations, premium pricing, and specialty distribution.
• Dermavant Sciences: Dermatology specialty company focused on innovative topical therapies (e.g., VTAMA cream for plaque psoriasis). Comparable to Nobelpharma in topical formulation expertise and rare/specialty dermatology positioning.
• Vertex Pharmaceuticals: Rare-disease specialty pharma focused on serious genetic conditions with limited treatment options. Similar business model and philosophy of developing transformative therapies for small patient populations, including dermatology-adjacent indications.
• Recordati Rare Diseases: Specialty pharma division focused exclusively on rare diseases with a portfolio spanning multiple therapeutic areas including metabolic and dermatology-adjacent rare conditions. Similar niche-orphan business model and geographic expansion strategy.

Emerging players

• Aclaris Therapeutics: Dermatology specialty company developing topical and immuno-inflammatory therapies. Comparable in topical drug delivery focus and rare/specialty dermatology indication strategy, though at earlier commercial stage.
• Sol-Gel Technologies: Dermatology specialty company with FDA-approved topical products for rare inflammatory skin conditions. Comparable topical dermatology focus and specialty pharma commercial model, though smaller scale.

Broad incumbents

• Mallinckrodt Pharmaceuticals: Specialty pharma with rare disease and dermatology franchises. Comparable specialty distribution model and focus on small-patient-population therapies with premium pricing.
• Pfizer (Rare Disease & Dermatology): Large incumbent with a rare disease portfolio and dermatology franchise (including acquired Anacor assets such as EUCRISA). Comparable on both axes but at vastly larger scale, representing the type of competitor that could enter TSC dermatology space.
• Alexion / AstraZeneca Rare Disease: Established rare-disease franchise within AstraZeneca focused on complement-mediated and rare metabolic diseases. Comparable commercial infrastructure for rare disease launches and similar regulatory expertise, though operates at much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nobelpharma